NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) - Dilution Analysis

8-K filing: Stock split 1-for-6 | Outstanding: 48,604,996 → 8,100,832

10-Q filing | 48.6M shares outstanding

10-Q filing | 49.8M shares outstanding

8-K filing: NeuroOne Medical Technologies Corporation closed an offering of 16,000,000 shares of common stock at a price of $0.50 per share with Ladenburg Thalmann & Co. Inc. as underwriter, and granted the underwriter an option to purchase an additional 2,400,000 shares.

10-Q filing | 30.9M shares outstanding

10-K filing | 30.8M shares outstanding

S-3/A filing: This prospectus relates to the resale of 5,552,784 shares of common stock by selling stockholders.

S-3 filing: NeuroOne Medical Technologies Corporation is offering 5,552,784 shares of common stock by selling stockholders, including shares issued in a private placement and shares issuable upon exercise of warrants.

10-Q filing | 30.8M shares outstanding

S-3/A filing: NeuroOne Medical Technologies Corporation files an S-3/A to offer and sell up to $150,000,000 of any combination of common stock, preferred stock, and debt securities from time to time.

8-K filing: NeuroOne Medical Technologies Corporation entered into a Securities Purchase Agreement for a private placement of 2,944,446 shares of common stock and warrants to purchase 2,208,333 shares at $0.90 per unit, resulting in gross proceeds of approximately $2.65 million, and also entered into a loan and security agreement for a delayed draw term loan facility of up to $3.0 million, issuing warrants for 100,000 shares of common stock at $0.66 per share at closing, with additional warrants to be issued upon borrowing. ($2.65M proceeds)

S-3 filing: NeuroOne Medical Technologies Corporation files an S-3 to offer from time to time an aggregate amount of up to $150,000,000 of any combination of common stock, preferred stock, and debt securities.

10-Q filing | 25.9M shares outstanding

10-Q filing | 24.0M shares outstanding

10-K filing | 24.0M shares outstanding

8-K filing: The company's board of directors adopted the First Amendment to the Company's Inducement Plan, increasing the aggregate number of shares of common stock that may be issued pursuant to equity incentive awards under the Inducement Plan by 420,350 shares for a total of 570,350 shares.

10-Q filing | 23.9M shares outstanding

8-K filing: NeuroOne Medical Technologies Corporation completed the sale and issuance of 6,037,500 shares of its common stock at a price of $1.00 per share, including the exercise in full of the Overallotment Option, resulting in net proceeds of approximately $5,214,875. ($6.04M proceeds)

10-Q filing | 16.4M shares outstanding

10-Q filing | 16.2M shares outstanding

10-K filing | 16.0M shares outstanding

10-Q filing | 16.2M shares outstanding

8-K filing: NeuroOne Medical Technologies Corporation issued a warrant to Zimmer to purchase up to 350,000 shares of common stock at an exercise price of $3.00 per share.

10-Q filing | 16.2M shares outstanding

10-Q filing | 16.2M shares outstanding

10-K filing | 16.2M shares outstanding

8-K filing: NeuroOne Medical Technologies Corporation entered into an Underwriting Agreement for the issuance and sale of 3,750,000 shares of common stock at a price of $3.20 per share, with an option for the underwriter to purchase an additional 562,500 shares, resulting in net proceeds of approximately $10,860,000 for working capital and general corporate purposes; the offering is expected to close on October 15, 2021. ($12.0M proceeds)

8-K filing: NeuroOne Medical Technologies Corporation adopted the 2021 Inducement Plan, reserving 420,350 shares of its common stock for grants of awards to new employees or directors.

10-Q filing | 12.0M shares outstanding

S-3 filing: The filing is an S-3 form for a shelf offering of up to $150,000,000 of common stock, preferred stock and/or debt securities from time to time.

10-Q filing | 12.0M shares outstanding

8-K filing: Stock split 1-for-3 | Outstanding: 22,180,674 → 7,386,164

S-1/A filing: The company is issuing 12,500,000 shares of Common Stock and warrants to purchase 12,500,000 shares of Common Stock at an aggregate purchase price of $1.00 per share and corresponding Warrant, resulting in total gross proceeds of $12.5 million. The warrants have an initial exercise price of $1.75 per share.

10-Q filing | 22.2M shares outstanding

S-1 filing: This S-1 filing relates to the registration of shares of Common Stock and Warrants by Selling Stockholders. The Selling Stockholders may be considered underwriters, and any commission paid to broker-dealers may be deemed underwriting commissions. A prospectus supplement will be distributed at the time of offering, detailing the amount of shares and terms of the offering. The Selling Stockholders are subject to Exchange Act provisions, and the shares will be freely tradable once sold.

10-K filing | 13.5M shares outstanding

POS AM filing: This is a POS AM filing providing a prospectus summary of NeuroOne Medical Technologies Corporation's offerings, including private placements, broker warrants, and series 3 note conversions.

8-K filing: NeuroOne Medical Technologies Corporation issued 120,000 restricted shares of common stock to an investor relations firm on August 31, 2020, for consulting services.

S-1/A filing: This S-1/A filing describes the offering of convertible promissory notes and warrants, as well as common stock offerings, between April 30, 2020 and July 28, 2020.

10-Q filing | 13.5M shares outstanding

S-1 filing: The company filed an S-1 form on 2020-08-12, which details the offering of convertible promissory notes, warrants, and common stock.

8-K filing: NeuroOne Medical Technologies Corporation sold 75,000 shares of common stock to an accredited investor for $135,000 in a private placement. ($0.14M proceeds)

8-K filing: NeuroOne Medical Technologies Corporation reports the conversion of $5,204,800.67 of convertible notes into 5,617,866 shares of common stock between May 1, 2020 and July 23, 2020.

8-K filing: NeuroOne Medical Technologies Corporation completed a private placement, issuing convertible notes and warrants. Additionally, some noteholders converted their notes into common stock.

8-K filing: NeuroOne Medical Technologies Corporation completed a private placement, issuing notes for $3,466,600 and warrants exercisable for 926,898 shares of common stock. Additionally, Subscribers converted $501,830.16 of notes into 497,854 shares of Common Stock.

10-Q filing | 13.5M shares outstanding

8-K filing: NeuroOne Medical Technologies Corporation completed a private placement, issuing convertible notes and warrants, and subsequently converted a portion of the notes into common stock.

8-K filing: NeuroOne Medical Technologies Corporation entered into a Subscription Agreement for a private placement issuing convertible promissory notes and warrants, and certain 2019 Subscribers converted $160,714.28 of notes into 118,894 shares.

8-K filing: NeuroOne Medical Technologies Corporation issued 1,996,198 shares of common stock upon conversion of $2,472,565.81 of convertible promissory notes between April 24 and April 29, 2020. ($2.47M proceeds)

8-K filing: NeuroOne Medical Technologies Corporation issued 22,500 shares of common stock to a consultant on February 17, 2020, for consulting services, with additional shares to be issued in the following months.

10-Q filing | 13.5M shares outstanding

8-K filing: NeuroOne Medical Technologies Corporation issued warrants to purchase 259,476 shares of common stock to affiliates of Paulson Investment Company, LLC at an exercise price of $1.87 per share.